TY -的T1 -改善灰质病变检测的女士使用MRI:比较双反转恢复和相敏反转恢复(S51.001) JF -神经学乔-神经病学SP - S51.001 LP - S51.001六世- 78 - 1补充非盟- Varun Sethi盟Tarek Yousry AU -尼尔斯·Muhlert盟-玛丽亚罗恩盟Xavier戈利盟克劳迪娅Wheeler-Ki首页ngshott AU -大卫·米勒盟Declan甜菜Y1 - 2012/04/26 UR - //www.ez-admanager.com/content/78/1_Supplement/S51.001.abstract N2 -目的:研究的程度,皮质分布通用在MS患者病变,健康对照组使用相敏反转恢复(PSIR)。背景的存在,分布,进化的白质病变MRI有助于诊断广泛女士皮层灰质(GM)参与histo-pathologically看到,但不使用传统的核磁共振。双反转恢复(DIR)增加检测转基因病变,但组织病理学观察。PSIR最近调查,以帮助改善通用损伤检测。设计/方法:30控件(平均年龄37.8±SD±11.8年),57例(46±11年)研究了{30复发汇款(RR)女士,12个主要(PP),15个二级进步(SP) MS)}。天赋,PD / T2, PSIR,DIR图像使用飞利浦阿奇沃3 t系统获得的。 Lesions were marked on PSIR & DIR independently(FLAIR &PD/T2 as reference). GM lesions(involved GM at any point) were marked. They were sub-classified as pure GM(involve only the GM) or mixed GM-white matter(WM) lesions. On PSIR, we also identified juxtacortical WM lesions(touching, not involving cortical GM), separate from mixed GM-WM lesions.Results: On DIR, number of pure GM lesions was (mean±SD) 4.3±5.1 in RR, 2.0±1.8 in PP, 8.5±4.8 in SPMS, & mixed GM-WM lesions was 9.5±11.0 in RR, 4.8±3.4 in PP and 21.4±10.3 in SPMS. On PSIR, mean number of pure GM lesions was 11.4±10.5 in RR, 6.6±4.5 in PP, 28.3±17.0 in SPMS, & mixed GM-WM lesions 15.4±15.8 in RR, 10±6.7 in PP & 39.3±21.0 in SPMS. When juxtacortical lesions were added to the number of GM-WM lesions, the counts were 18.7±17.9 in RR, 12.5±7.9 in PP & 50.2±27.7 in SPMS. On PSIR, pure GM lesion was seen in 1/30 healthy controls and in 49/57 patients.Conclusions: PSIR identifies 2-3x more GM lesions than DIR. Apparently pure GM were seen in ∼80% of patients, but <5% controls, suggesting that PSIR may have a role in the diagnosis of MS.Supported by: MS Society of Great Britain and Northern Ireland.Disclosure: Dr. Sethi has received personal compensation for activities with Biogen Idec and Novartis. Dr. Sethi has received research support from the Multiple Sclerosis Society of Great Britain and Northern Ireland. Dr. Yousry has received personal compensation in an editorial capacity for European Radiology Journal. Dr. Yousry has received compensation for serving on the board of Biogen Idec, Bristol-Myers Squibb, and UCB Pharma. Dr. Yousry has received research support from Biogen Idec, British Heart Foundation, GlaxoSmithKline, Inc., Medical Research Council, MS Society of Great Britain and Northern Ireland, NIHR Comprehensive Biomedical Research Centre, Novartis, PSP Association, Stroke Association, and Wellcome Trust. Dr. Muhlert has nothing to disclose. Dr. Ron has nothing to disclose. Dr. Golay has nothing to disclose. Dr. Wheeler-Kingshott has nothing to disclose. Dr. Miller has received personal compensation for activities with UCL Institute of Neurology, Biogen Idec, GlaxoSmithKline, and Bayer Schering Pharma. Dr. Miller has received personal compensation in an editorial capacity for Journal of Neurology. Dr. Miller has received research support from GlaxoSmithKline, Biogen Idec, and Novartis. Dr. Chard holds stock and/or stock options in GlaxoSmithKline, Inc. Dr. Chard has received research support from the Multiple Sclerosis Society of Great Britain and Northern Ireland.Thursday, April 26 2012, 15:00 pm-16:30 pm ER -